<DOC>
	<DOCNO>NCT02663700</DOCNO>
	<brief_summary>This study phase 1 , randomize , double-blind , placebo-controlled , dose escalation trial Sanaria 's irradiated sporozoite vaccine ( PfSPZ vaccine ) . The primary objective protocol determine safety reactogenicity PfSPZ Vaccine malaria-experienced healthy adult . The study duration shall 34 month subject participation duration shall 15-26 month .</brief_summary>
	<brief_title>Safety Immunogenicity Sanaria 's Irradiated Sporozoite Vaccine ( PfSPZ Vaccine ) Malaria-Experienced Adults Burkina Faso</brief_title>
	<detailed_description>This study phase 1 , randomize , double-blind , placebo-controlled , dose escalation trial Sanaria 's irradiated sporozoite vaccine ( PfSPZ vaccine ) . The primary objective protocol determine safety reactogenicity PfSPZ Vaccine malaria-experienced healthy adult . The secondary protocol objective evaluate vaccine-induced immune response , include limited , anti-CSP antibody T cell response whole P. falciparum sporozoites variety P. falciparum antigens different life cycle stage . The study duration shall 34 month subject participation duration shall 15-26 month .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>1 . A male nonpregnant female age 2140 year inclusive time screen . 2 . For woman , willingness become pregnant 1 month last vaccination Note : Premenopausal female participant refer local family planning clinic , offer several mean contraception approve recommended Burkina Faso Ministry Health . Contraception ( male female condom , diaphragm cervical cap spermicide , intrauterine device , hormonebased contraceptive ) start 30 day first vaccination continue 30 day last vaccination . 3 . Written inform consent obtain participant screen 4 . Available willing participate followup duration study 5 . Residing Sapone region environs 6 . Appear generally good health base clinical laboratory investigation 1 . Previous vaccination investigational malaria vaccine 2 . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day first study vaccination , plan use 30 day last vaccination 3 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month first vaccination . This include dose level oral steroid , inhaled steroid topical steroid . 4 . Planned administration/administration vaccine foreseen study protocol within 30 day first study vaccination exception tetanus toxoid 5 . Confirmed suspected immunosuppressive immunodeficient condition 6 . Confirmed suspected autoimmune disease 7 . History allergic reaction anaphylaxis artesunate artemisinin derivative , vaccination vaccine component 8 . History serious allergic reaction substance , require hospitalization emergent medical care 9 . History allergy component vaccine formulation , include human serum albumin 10 . Use plan use drug antimalarial activity course study except antimalarial medication administer study clinician 11 . History splenectomy 12 . Confirmed suspected pregnancy current breastfeeding 13 . Laboratory evidence liver disease ( ALT &gt; 1.25 x upper limit normal ) 14 . Laboratory evidence renal disease ( serum plasma creatinine &gt; upper limit normal ) 15 . Laboratory evidence hematologic disease ( platelet count &lt; 115,000/mm^3 , hemoglobin &lt; 11.2 g/dL male &lt; 9.5 g/dL female ) . 16 . Seropositive hepatitis B surface antigen hepatitis C virus ( hepatitis C antibody ) 17 . Seropositive HIV 18 . Sickle cell trait carriage sickle cell disease 19 . Administration immunoglobulin and/or blood product within three month precede first study vaccination plan administration study period . 20 . Simultaneous participation interventional clinical trial 21 . Acute chronic pulmonary , cardiovascular , hepatic , renal neurological condition , severe malnutrition , clinical finding may increase risk participate study , determine PI 22 . Other condition opinion PI would jeopardize safety right participant trial would render participant unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 12, 2016</verification_date>
	<keyword>Burkina Faso</keyword>
	<keyword>healthy adult</keyword>
	<keyword>Irradiated</keyword>
	<keyword>malaria</keyword>
	<keyword>PfSPZ Vaccine</keyword>
	<keyword>Sanaria</keyword>
	<keyword>Sporozoite</keyword>
	<keyword>Vaccine</keyword>
</DOC>